TeLuRide-005: Phase 2 Study of EIK1001 (TLR 7/8 Dual Agonist) Plus Pembrolizumab and Chemotherapy in Patients with Stage IV NSCLC: Results from the Squamous Cohort and Updated Pooled Results-ESMO Poster